Psoriatic arthritis - What the dermatologist needs to know

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 11, 2010, Pages 1270-1277

  Laws, P ^a   Barton, A ^b   Warren, R B ^a  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Psoriasis; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 23; LEFLUNOMIDE; LEUKOCYTE ANTIGEN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB;

ANEMIA; ARTHRALGIA; ARTHROPATHY; BONE MARROW SUPPRESSION; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; COMORBIDITY; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; EDEMA; ENTHESITIS; ERYTHROCYTE SEDIMENTATION RATE; EXERCISE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INJECTION SITE REACTION; JOINT EFFUSION; KIDNEY DISEASE; LEUKOCYTOSIS; LIVER TOXICITY; LOADING DRUG DOSE; LOW BACK PAIN; LOW DRUG DOSE; LUNG FIBROSIS; LYMPHEDEMA; MALAISE; MEMBRANOUS GLOMERULONEPHRITIS; MORNING STIFFNESS; NAIL DYSTROPHY; NEPHRITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; PATIENT CARE; PHALANX; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; RASH; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SACROILIITIS; SERODIAGNOSIS; SEROLOGY; SPONDYLITIS; SYNOVITIS; TOPICAL TREATMENT; TUBERCULOSIS; ULTRASOUND; VIRUS HEPATITIS; X RAY;

ARTHRITIS, PSORIATIC; DERMATOLOGY; DIAGNOSIS, DIFFERENTIAL; HUMANS;

EID: 78649743333     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03654.x     Document Type: Review

References (65)

1. Gottlieb A, Korman NJ, Gordon KB et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008; 58: 851-864. (Pubitemid 351509657)
2. Kane D, Stafford L, Bresnihan B et al. A prospective, clinical and radiological study of early psoriatic arthritis: An early synovitis clinic experience. Rheumatology (Oxford) 2003; 42: 1460-1468.
3. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78.
4. Brockbank JE, Stein M, Schentag CT et al. Dactylitis in psoriatic arthritis: A marker for disease severity? Ann Rheum Dis 2005; 64: 188-190.
5. Buskila D, Langevitz P, Gladman DD et al. Patients with rheumatoid arthritis are more tender than those with psoriatic arthritis. J Rheumatol 1992; 19: 1115-1119.
6. Battistone MJ, Manaster BJ, Reda DJ et al. The prevalence of sacroilitis in psoriatic arthritis: New perspectives from a large, multicenter cohort. A Department of Veterans Affairs Cooperative Study. Skeletal Radiol 1999; 28: 196-201.
7. Taylor W, Gladman D, Helliwell P et al. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-2673.
8. Cohen MR, Reda DJ, Clegg DO. Baseline relationships between psoriasis and psoriatic arthritis: Analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol 1999; 26: 1752-1756.
9. Ory PA, Gladman DD, Mease PJ. Psoriatic arthritis and imaging. Ann Rheum Dis 2005; 64 Suppl 2: Ii55-57.
10. Rahman P, Gladman DD, Cook RJ et al. Radiological assessment in psoriatic arthritis. Br J Rheumatol 1998; 37: 760-765.
11. Sharp JT, Bluhm GB, Brook A et al. Reproducibility of multiple-observer scoring of radiologic abnormalities in the hands and wrists of patients with rheumatoid arthritis. Arthritis Rheum 1985; 28: 16-24.
12. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000; 27: 261-263.
13. Ruckmann A, Ehle B, Trampisch HJ. How to evaluate measuring methods in the case of non-defined external validity. J Rheumatol 1995; 22: 1998-2000.
14. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-2272.
15. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279-3289.
16. Antoni C, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64: 1150-1157.
17. Wiell C, Szkudlarek M, Hasselquist M et al. Ultrasonography, magnetic resonance imaging, radiography, and clinical assessment of inflammatory and destructive changes in fingers and toes of patients with psoriatic arthritis. Arthritis Res Ther 2007; 9: R119.
18. McGonagle D. Enthesitis: An autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol 2009; 1: 9-13.
19. Gladman DD, Farewell VT. Progression in psoriatic arthritis: Role of time varying clinical indicators. J Rheumatol 1999; 26: 2409-2413.
20. Johnson SR, Schentag CT, Gladman DD. Autoantibodies in biological agent naive patients with psoriatic arthritis. Ann Rheum Dis 2005; 64: 770-772.
21. Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T et al. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003; 62: 68-70.
22. McCarey D, McInnes IB. Psoriatic arthritis: Current topics. Curr Rheumatol Rep 2007; 9: 442-448.
23. Setty AR, Choi HK. Psoriatic arthritis epidemiology. Curr Rheumatol Rep 2007; 9: 449-454.
24. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA et al. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004; 34: 585-592.
25. Gelfand JM, Troxel AB, Lewis JD et al. The risk of mortality in patients with psoriasis: Results from a population-based study. Arch Dermatol 2007; 143: 1493-1499.
26. Miele L, Vallone S, Cefalo C et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 778-786.
27. Poikolainen K, Reunala T, Karvonen J et al. Alcohol intake: A risk factor for psoriasis in young and middle aged men? BMJ 1990; 300: 780-783.
28. Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: Results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-67.
29. Fortes C, Mastroeni S, Leffondre K et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 2005; 141: 1580-1584.
30. Herron MD, Hinckley M, Hoffman MS et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-1534.
31. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007; 167: 1670-1675.
32. Husni ME, Meyer KH, Cohen DS et al. The PASE questionnaire: Pilottesting a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 2007; 57: 581-587.
33. Gladman DD, Schentag CT, Tom BD et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: The Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis 2009; 68: 497-501.
34. Gladman DD, Helliwell P, Mease PJ et al. Assessment of patients with psoriatic arthritis: A review of currently available measures. Arthritis Rheum 2004; 50: 24-35.
35. Mease PJ, Antoni CE, Gladman DD et al. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 Suppl 2: Ii49-54.
36. Chandran V, Gottlieb A, Cook RJ et al. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Rheum 2009; 61: 1235-1242.
37. Fransen J, Antoni C, Mease PJ et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: Analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006; 65: 1373-1378.
38. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: A proposed objective target for treatment. Ann Rheum Dis 2010; 69: 48-53.
39. Ritchlin CT, Kavanaugh A, Gladman DD et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-1394.
40. Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: Results from a longitudinal observational cohort. J Rheumatol 2008; 35: 469-471.
41. Belzunegui J, Intxausti JJ, De Dios JR et al. Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate. Clin Exp Rheumatol 2001; 19: 727-730.
42. Helliwell PS, Taylor WJ. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs - comparison of drugs and adverse reactions. J Rheumatol 2008; 35: 472-476.
43. Chalmers RJ, Kirby B, Smith A et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: A multicentre audit and health economic analysis. Br J Dermatol 2005; 152: 444-450.
44. Zachariae H, Heickendorff L, Sogaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate- induced liver fibrosis: A 10-year follow-up. Br J Dermatol 2001; 144: 100-103.
45. Clegg DO, Reda DJ, Mejias E et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39: 2013-2020. (Pubitemid 27009069)
46. Salvarani C, Macchioni P, Olivieri I et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001; 28: 2274-2282.
47. Kaltwasser JP, Nash P, Gladman D et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004; 50: 1939-1950.
48. Palit J, Hill J, Capell HA et al. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol 1990; 29: 280-283.
49. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486-497.
50. Adalimumab for the treatment of adults with psoriasis. http://www.nice.org.uk/nicemedia/pdf/TA146Guidance. pdf. In: National Institute for Clinical Excellence. 2008.
51. Etanercept and efalizumab for the treatment of adults with psoriasis. http://www. nice. org. uk/nicemedia/pdf/TA103guidance. pdf. In: National Institute for Clinical Excellence. 2006.
52. Infliximab for adults with psoriasis. http://www. nice. org. uk/nicemedia/pdf/TA134Guidance. pdf. In: National Institute for Clinical Excellence. 2008.
53. Adalimumab for the treatment of psoriatic arthritis. http://www.nice.org. uk/nicemedia/pdf/TA125guidance. pdf. In: National Institute for Clinical Excellence. 2007.
54. Etanercept and infliximab for the treatment of adults with psoriatic arthritis. http://www. nice. org. uk/nicemedia/pdf/TA104guidance. pdf. In: National Institute for Clinical Excellence. 2006.
55. Gladman DD, Mease PJ, Ritchlin CT et al. Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007; 56: 476-488.
56. Genovese MC, Mease PJ, Thomson GT et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007; 34: 1040-1050.
57. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52: 1227-1236.
58. Kavanaugh A, McInnes I, Mease P et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60: 976-986.
59. Gladman D, Kavanaugh A, McInnes I et al. Golimumab, a new human TNF-alpha antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: Nail, enthesitis, and dactylitis response in the randomized, placebo controlled, GO-REVEAL study. Abstract presented at the European League Against Rheumatism, 2008, Paris.
60. Choy EH, Hazleman B, Smith M et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: A phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002; 41: 1133-1137.
61. Melmed GY, Targan SR, Yasothan U et al. Certolizumab pegol. Nat Rev Drug Discov 2008; 7: 641-642.
62. Liu Y, Helms C, Liao W et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008; 4: E1000041.
63. Ritchlin C, Haas-Smith SA, Hicks D et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25: 1544-1552.
64. Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633-640.
65. Kimball AB, Gordon KB, Langley RG et al. Safety and efficacy of ABT- 874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: Results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008; 144: 200-207.